The bromocriptine-induced reduction in liver and adipose fat content is associated with and may derive in part from reductions of hyperinsulinemia, liver lipogenic responsiveness to insulin and pro-inflammatory pathways that potentiate lipogenic activity. The gene discussed is INS; the disease is Hyperinsulinemia.